
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
President and Chief Executive Officer Mary Szela said the company’s first-quarter results reflected the “deliberate cost of a build-out phase” as TriSalus expanded and realigned its sales organization to support growth in liver embolization and new applications for its Pressure-Enabled Drug Delivery, or PEDD, platform.